Pharmacogenetics-guided dose modifications of antidepressants

Area of Science:

• Pharmacogenomics
• Drug Metabolism
• Enzyme Kinetics

Background:

• Drug efficacy is influenced by patient-specific factors including genetics.
• Genetic polymorphisms in drug-metabolizing enzymes cause variable drug responses.
• Altered enzyme activity can lead to therapeutic failure or adverse drug reactions.

Purpose of the Study:

• To highlight the impact of genetic polymorphisms on drug metabolism.
• To emphasize the role of CYP2D6 and CYP2C19 in metabolizing various drugs.
• To advocate for personalized drug therapy based on genetic profiles.

Main Methods:

• Review of literature on pharmacogenetics and drug metabolism.
• Analysis of the role of polymorphic enzymes in drug response.
• Identification of key cytochrome P450 enzymes (CYP2D6, CYP2C19).

Main Results:

• Genetic polymorphisms lead to slow or rapid drug metabolism.
• Slow metabolism increases risk of adverse drug reactions.
• Rapid metabolism can result in therapeutic failure.
• CYP2D6 and CYP2C19 are crucial for metabolizing antidepressants and other drugs.

Conclusions:

• Knowledge of genetic polymorphisms aids in selecting appropriate drug agents and dosages.
• Personalized medicine approaches can improve drug therapy outcomes.
• Pharmacogenetic testing can optimize treatment for drugs with narrow therapeutic indices.